On November 2, 2026, FDA published a proposed rule that would change the required levels of four nutrients in infant formula: iodine, vitamin A, vitamin D and manganese. It is the first phase of FDA's first comprehensive review of the infant formula nutrient table in 21 CFR 107.100 since 1998, a review that grew out of the agency's Operation Stork Speed initiative. Comments are due March 2, 2027, in docket FDA-2026-N-10832.
What would change
The proposal covers 8 of the 30 required nutrients. Four would change. All amounts are per 100 kilocalories, and µg means micrograms:
Iodine would move from 5–75 µg to 15–50 µg.
Vitamin A would move from 75–225 µg retinol activity equivalents (RAE) to 70–120 µg RAE, and only preformed vitamin A would count. Beta-carotene could stay in the formula but would not count toward the required level.
Vitamin D would move from 1–2.5 µg to 2–3 µg.
Manganese would get its first maximum, 50 µg, while the minimum drops from 5 µg to 1 µg.
Chloride, potassium, selenium and sodium would stay where they are. Labels would also have to declare vitamins A and D in micrograms instead of international units (IU), with IU allowed in parentheses. That part applies even to formulas whose nutrient levels already fit the new ranges, and FDA estimates about 326 products will need new labels.
Who it affects
The rule would reach every product that meets the statutory definition of infant formula, whether made here or abroad. FDA's cost analysis expressly counts foreign manufacturers, so U.S. importers should expect their suppliers' formulas to be measured against the same table. Soy-based formulas are the obvious pressure point. FDA itself says 50 µg of manganese may be the lowest level soy protein formulas can technically reach, and it asks for comment on feasibility. Any formula that relies on beta-carotene to meet its vitamin A minimum will also need a closer look.
Timing
Nothing is binding yet. As proposed, a final rule would take effect 60 days after publication, and companies would have three years after that to comply. FDA describes this as the first of three phases. Later phases will take up the remaining nutrients and possible new requirements, and this proposal already asks for input on docosahexaenoic acid (DHA), arachidonic acid (ARA) and L-carnitine. A product team planning one reformulation should keep that in mind.
What to do now
Check current specifications and stability data against the proposed ranges, starting with vitamin A sources and manganese in soy-based products. Reformulating infant formula can bring in FDA's existing notification requirements under 21 CFR Part 106, so plan the regulatory review into the three-year window rather than treating this as label work. If the ranges do not work for your product, the comment period is the time to say so, with data. FDA has asked specific questions about manganese, whether the vitamin D maximum should be lower for younger infants, and the compliance date, and comments that answer those questions tend to carry more weight than general objections.
How MDRXLaw can help
We help infant formula and food manufacturers and importers assess proposed rules against their products, prepare comments, and plan reformulation, relabeling and FDA submissions. To talk through your formulas, contact us at info@mdrxlaw.com or 212-668-0200.
Sources: Federal Register, Infant Formula Nutrient Requirements (proposed rule); FDA, Letter to Tribal Leaders (October 29, 2026). This alert is for general information and is not legal advice.

